{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '12.10.5 Duration of Treatment and Discontinuation Criteria', 'A discontinuation from treatment is a subject who enrolled in the COE and for whom study', 'treatment is permanently discontinued for any reason.', 'The subject is free to discontinue from study treatment and/or withdraw from the COE study', 'for any reason and at any time without giving reason for doing so and without penalty or', 'prejudice. The investigator is also free to discontinue the subject from COE study treatment', \"or to terminate a subject's involvement in the study at any time if the subject's clinical\", 'condition warrants it.', 'All subjects who discontinue COE study treatment will remain in the study and must', 'continue to be followed for protocol specific follow up procedures as outlined in the COE', 'Schedule of Assessments', 'Table 11 until the subject specifically withdraws consent for any', 'further contact with him/her or persons previously authorized by the participant to provide', 'this information.', 'If a subject is discontinued from the study with an ongoing AE or an unresolved laboratory', 'result that is significantly outside of the reference range, the investigator will attempt to', 'provide follow-up until the condition stabilizes or no longer is clinically significant.', 'The following are discontinuation criteria from treatment for individual subjects:', 'Subject develops radiological disease progression relative to scan performed within 28', 'days of COE C1D1 dose.', 'Subject is required to receive another systemic anti-cancer treatment for underlying or', 'new cancer', 'Subject develops unacceptable toxicity', 'Female subject becomes pregnant', \"Investigator decides it is in the subject's best interest to discontinue.\", 'Subject declines further treatment', 'Subject is noncompliant with the protocol based on the investigator or medical monitor', 'assessment.', 'Subject is lost to follow-up despite reasonable efforts by the investigator to locate the', 'subject.', 'Death.', 'The subject will be discontinued from the long-term PFS2 follow-up period if any of the', 'following occur:', 'Subject initiates a new systemic anticancer treatment', 'Subject exhibits evidence of PD based on investigator assessment', 'Subject declines further study participation (i.e., withdraws consent)', 'Subject is lost to follow-up despite reasonable efforts by the investigator to locate the', 'subject', 'Death', 'Sponsor ends long-term follow-up collection period', '14 Sep 2020', 'Astellas', 'Page 126 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'The subject will be discontinued from the survival follow-up period if any of the following', 'occur:', 'Subject declines further study participation (i.e., withdraws consent)', 'Subject is lost to follow-up despite reasonable efforts by the investigator to locate the', 'subject', 'Death', 'Sponsor ends survival follow-up collection period', '12.10.6 Statistical Methods', 'All eligible Arm B subjects who cross to COE EV treatment will be the analysis population,', 'and analyzed in the same way as described in [Section 7 Statistical Methodology] for all', 'applicable safety endpoints with data collected in COE period unless otherwise specified in', 'SAP. The following analysis will be provided:', 'Study population in COE period:', 'Disposition at EOT, 30-day follow-up, long-term follow-up and survival follow-up', 'Days in the study and previous study treatment outcomes at the time initiating the', 'EV treatment', 'Major protocol deviations in COE period', 'Demographics and other characteristics at original study enrollment', 'Concomitant medications in COE period.', 'Study drug exposure in COE period', 'Analysis of safety in COE period:', 'Adverse events', 'Lab assessments', 'Vital signs', '12-lead ECG', 'ECOG performance status', 'Details will be specified in the SAP.', '14 Sep 2020', 'Astellas', 'Page 127 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}